BMY240809P45500
- 0.02
- -0.04-66.67%
Bristol-Myers Squibb Newsroom
Healthcare Stocks Are Closing the Gap. Here Are the Latest Winners.
74 S&P 500 Stocks That Can Beat the Cash Yield - BofA
Bristol Myers Stock (NYSE:BMY): Perfect Place to Wait Out Market Volatility
Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ
Evotec Gets $25 Million From Bristol Myers Squibb Partnership
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Evotec Advances Strategic Neuroscience Partnership With Bristol Myers Squibb, Earning $25M Milestone Payment
Bristol Myers Cited by FDA for Misleading Claims on Krazati Website
Smart Money Is Betting Big In BMY Options
Unusual Options Activity: BMY, NTRA and Others Attract Market Bets, BMY V/OI Ratio Reaches 227.3
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Bristol-Myers Squibb Company PFD CONV 2 Goes Ex Dividend Tomorrow
Daiwa Securities Adjusts Bristol-Myers Squibb Price Target to $50 From $40
Bristol Ends Licensing Agreement With Agenus on TIGIT Bispecific Antibody
Express News | Agenus Inc - Bms Will Assign to Co All Regulatory Registrations, Applications, Authorizations, Approvals That Bms Holds in Connection With Agen1777
Express News | Agenus Inc - Will Have Right to Continue Development or Enter a Subsequent License in Future
Express News | Agenus Inc - Will Not Incur Any Early Termination Penalties as a Result of Termination
Express News | Agenus Inc - on July 30, Received Notice From Bms That It Is Voluntarily Terminating Bms License Agreement, Effective as of January 26, 2025
Express News | Agenus Inc - on July 30 Received Notice From Bristol Myers Squibb,It Is Returning Agen1777 Back to Agenus
HSBC Adjusts Bristol-Myers Squibb Price Target to $50 From $45